Pharmaceutical Information |
Drug Name |
Frovatriptan |
Drug ID |
BADD_D00976 |
Description |
Frovatriptan is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. |
Indications and Usage |
For the acute treatment of migraine attacks with or without aura in adults. |
Marketing Status |
approved; investigational |
ATC Code |
N02CC07 |
DrugBank ID |
DB00998
|
KEGG ID |
D07997
|
MeSH ID |
C108128
|
PubChem ID |
77992
|
TTD Drug ID |
D06FPQ
|
NDC Product Code |
Not Available |
UNII |
H82Q2D5WA7
|
Synonyms |
frovatriptan | 3-methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole | Frova | VML-251 | VML251 | Frovelan | SB 209509 | Allegro | frovatriptan succinate | (+)-(R)-5,6,7,8-tetrahydro-6-(methylamino)carbazole-3-carboxamide succinate (1:1), monohydrate |
|
Chemical Information |
Molecular Formula |
C14H17N3O |
CAS Registry Number |
158747-02-5 |
SMILES |
CNC1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N |
Chemical Structure |
|
|
ADRs Induced by Drug |
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|